Objective: To review the management of hepatic encephalopathy (HE), including lifestyle modifying strategies and pharmacological interventions. Data Sources: A literature search of PubMed through March 2016 was conducted utilizing the keywords hepatic encephalopathy, ammonia, and cirrhosis. All published articles evaluating treatments for HE were considered. Study Selection and Data Extraction: Available English-language data from reviews, abstracts, presentations, and clinical trials of the treatment of HE in humans were reviewed; relevant clinical data were selected and included. Data Synthesis: HE is a prevalent complication of portal hypertension and cirrhosis that results in altered mental status and neuropsychiatric impairment. Although the pathogenesis has not been elucidated, numerous treatment options exist. This review will explore the role of dietary interventions and supplements, including use of zinc, acetyl-l-carnitine, and probiotics, in the management of HE. Additionally, the use of various ammonia-lowering agents will be evaluated. The nonabsorbable disaccharides represent first-line therapies for the management and prophylaxis of HE; rifaximin use has been demonstrated to be effective for both treatment and prophylaxis of HE symptoms, with use relegated to those patients who fail to respond to or tolerate the nonabsorbable disaccharides. In light of toxicities associated with the use of neomycin and metronidazole, recent guidelines recommend both as alternatives for the treatment of HE, with the use of vancomycin discouraged. Conclusion: Although numerous treatment options are available, management of HE remains a clinical challenge. Additional research is needed to explore the pathogenesis and better understand the role of pharmacotherapy in managing this condition.
Introduction
The burden of cirrhosis is rising; approximately 5.5 million Americans have hepatic cirrhosis of the liver. 1 In 2010, chronic liver disease with cirrhosis was reported to be the 12th leading cause of death in the United States, with approximately 31 903 cirrhosis-related deaths per 100 000 population reported. 1 Hepatic encephalopathy (HE) represents one of the many complications of portal hypertension and liver disease, and it is estimated to be present in 50% to 70% of patients with cirrhosis. 2 HE is associated with a spectrum of neuropsychiatric impairment and neuromuscular abnormalities contributing to tremendous health care resource utilization, both in direct and indirect costs, as well as substantial morbidity and mortality. Approximately 23 000 patients were hospitalized for HE in 2009, with an average length of acute care stay of 8.5 days, at a cost of $63 108 per case and an estimated mortality rate of 15%. 3 HE can present with varying severity, categorized into either covert (minimal) HE (CHE) or overt HE (OHE). 4 OHE consists of neurological and psychiatric abnormalities that can be detected by bedside clinical tests, whereas CHE can only be distinguished by specific psychometric tests because these patients have normal mental and neurological status on clinical exam. OHE occurs in at least 30% to 45% 645826A OPXXX10.1177/1060028016645826Annals of PharmacotherapyJawaro et al research-article2016 of patients with cirrhosis and in 10% to 50% of patients with transjugular intrahepatic portosystemic shunts. CHE is estimated to develop in more than 60% of patients with cirrhosis. 5 Overt occurrences of HE are incapacitating, can occur without warning, render the patient incapable of self-care, and often represent a significant cause of hospitalization. 6, 7 Despite the high prevalence and aforementioned burden, little progress has been made over the years in this area because of the complex pathogenesis, which has not been fully elucidated. Moreover, there is lack of a universally accepted definition, diagnostic criteria, classification, or treatment guidelines for management of HE, primarily because of insufficient clinical research and availability of standardized definitions.
The burden of HE is enormous given its impact on the patient, family members, society, and health care system. It is imperative for clinicians to recognize and treat HE in an effort to prevent complications. This article reviews the pathophysiology, diagnostic criteria, and nonpharmacological and pharmacological interventions for HE as well as novel approaches to managing HE.
Methods for Selection and Assessment of Literature
A literature search was performed utilizing the PubMed database through March 2016. Search terms included hepatic encephalopathy, ammonia, and cirrhosis. All published articles pertaining to the management of HE were reviewed. Available English-language data from reviews, abstracts, presentations, information obtained from pharmaceutical companies, and clinical trials of agents utilized in the management of HE in humans were evaluated; relevant clinical data were selected and included. Bibliographic citations of research articles were also reviewed for comprehensive identification of pertinent literature.
Etiology and Pathophysiology
Hepatic encephalopathy is a term used to describe neurological and psychiatric manifestations of liver disease; this could sometimes occur as a result of portosystemic shunting (PSS). Patients with acute or chronic liver disease or PSS may present with varying degrees of brain dysfunction, ranging from minimal deficits only substantiated on objective tests to euphoria, confusion, and coma. 8 A full understanding of HE pathogenesis, as described, is still unclear; however, multiple different theories have emerged. 8 One of the earliest theories postulates elevated levels of blood ammonia for the associated neurological and psychiatric sequelae of HE. Ammonia is a byproduct of protein breakdown by gut bacteria. The liver metabolizes ammonia to urea and glutamine. However, in the setting of disease or PSS, the liver is unable to metabolize ammonia.
Thus, there is a surplus of ammonia available for metabolism by glutamine synthetase found in muscle and brain tissue. 9 In acute liver disease, sudden exposure of astrocytes to elevated levels of ammonia leads to brain edema and intracranial hypertension. On the other hand, chronic exposure of astrocytes to elevated levels of ammonia allows for compensatory mechanisms to accommodate increased intracellular water, and there is a resultant downregulation of glutamate. 10, 11 Other mechanisms postulated for chronic HE include increased blood-brain barrier permeability to nonlipid, polar substances such as γ-aminobutyric acid (GABA); decreased activity of GABA-transaminase, the enzyme responsible for metabolism of GABA; and accumulation of endogenous substances that bind to the benzodiazepine site of the GABA receptor. 10
Clinical Staging and Diagnosis
HE is classified based on 4 factors: the underlying cause, severity of manifestations, time course, and existence of precipitating factors. Figure 1 details this classification process. Note that type A HE manifests differently from types B and C. As a result, the severity classification of HE only applies to type B and C HE and is based on the West-Haven Criteria (WHC) and the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). 8 HE is a diagnosis of exclusion, and the clinician must rule out other causes of brain dysfunction, including medication-related cognitive impairment, illicit drug use, alcohol intoxication and withdrawal, medical comorbidity, hyponatremia, Wernicke's encephalopathy, and psychiatric illness. Patients with OHE commonly present with disorientation with or without asterixis, whereas patients with CHE present with more subtle signs and symptoms. The WHC (Table 1) is the gold standard tool used to grade OHE. In patients who present with altered consciousness, the Glasgow Coma Scale is often used as a descriptive tool. Psychometric or neuropsychological tests are used as HE diagnostic tools. Of note, 2 different validated tests should be utilized. As for laboratory findings, an elevated blood ammonia level should only be used for confirmation of diagnosis; it does not add to staging, prognosis, or response to therapy. Patients will usually receive a computed tomography scan or magnetic resonance imaging as part of the workup for other causes of altered mental status. 8
Treatment Goals
The latest practice guidelines for managing HE associated with chronic liver disease do not clearly state goals of treatment. 8 However, guidelines from the Practice Parameters Committee of the American College of Gastroenterology have identified treatment goals. These include the provision of supportive care, identification and removal of precipitating factors, reduction of nitrogenous load from the gut, and assessment of the need for long-term therapy. 12
Nonpharmacological Interventions: Nutrition and Dietary Modification

Branched-Chain Amino Acids
There is an imbalance between aromatic amino acids (AAAs) and branched-chain amino acids (BCAAs) in cirrhosis, specifically an increase in AAAs and a decrease in the BCAAs. 13, 14 In 2015, the Cochrane Collaboration published a systemic review of 827 patients in 16 randomized clinical trials in which use of oral or intravenous BCAAs was compared with placebo, diet, lactulose, or neomycin. BCAAs were found to have a beneficial effect on manifestations of HE. More specifically, subgroup analysis showed benefit of BCAAs on OHE in contrast to no effect on minimal HE (MHE) and a beneficial effect of oral BCAAs and not intravenous BCAAs. The beneficial effect of BCAAs was only seen when comparing BCAA with placebo, and there was no beneficial effect when limiting the analysis to BCAAs compared with lactulose or neomycin. The studies reported gastrointestinal discomfort as the main adverse reaction associated with BCAAs; no serious adverse events were reported. Of note, BCAAs were not found to improve quality of life. At the same time, they did not negatively affect quality of life. In summary, oral BCAAs may be beneficial in patients with OHE and may result in symptomatic improvement with little toxicity. 15 
Vegetable Proteins
In 2008, the ISHEN appointed an expert panel to develop a consensus document on the nutritional management of patients with HE. The expert panel emphasized that low protein diets should be avoided, with an exception in the setting of a gastrointestinal bleed. 16 Patients with HE not only have a higher energy expenditure, but lack of protein ingestion leads to skeletal muscle protein breakdown, resulting in release of amino acids and subsequent increase in the blood ammonia load. [16] [17] [18] Moreover, Amodio et al 16 suggested the use of vegetable and dairy protein over animal protein sources. Postulated mechanisms behind the benefit of vegetable protein over animal protein include lowered blood ammonia levels, increased fiber content leading to increased nitrogen clearance via the stool, and ammonia trapping. 17 
Zinc
Patients with HE have a deficiency of zinc attributed to poor nutritional status, impaired intestinal absorption, excessive urinary loss from diuretic use, and reduced binding to albumin because of decreased circulating levels. [19] [20] [21] In the setting of HE, zinc deficiency results in decreased activity of muscle glutamine synthetase, an important enzyme in reducing blood ammonia levels, as discussed previously. Thus, zinc serves as an important factor in ammonia detoxification. 16, 22 The ISHEN nutrition management consensus document states that additional research on the role and effects of zinc in HE is needed because of conflicting evidence. 16 In the same year in which the ISHEN consensus document was published, Chavez-Tapia et al 23 published a meta-analysis of the use of zinc supplementation versus placebo, standard therapy, or no intervention for the treatment of HE. Four prospective randomized trials of adult patients diagnosed with liver cirrhosis, hyperammonemia, and HE were analyzed. Authors of this analysis found that the use of zinc significantly improved performance on the number connection tests. 23 Yet zinc had no significantly beneficial effect on HE recurrence. 24 The doses studied included zinc sulfate 600 mg/d or zinc acetate 600 mg/d or polaprezinc 225 mg/d. Zinc was well tolerated, with only 1 patient experiencing nausea and vomiting. 23 Zinc may improve psychometric test measures; however, its use is not likely to prevent HE recurrence.
Acetyl-l-Carnitine
Acetyl-l-carnitine, the acetylated form of l-Carnitine, possesses neuroprotective properties, with some benefit found in the treatment of patients with HE. A systematic review of oral acetyl-l-carnitine found significant improvement in blood ammonia levels and time to complete the number connection test. It was well tolerated, with no major adverse events reported. Although acetyl-l-carnitine did improve blood ammonia levels, this is not indicative of adequate response. Overall, it did yield improvements in psychometric testing, with minimal side effects, in comparison to placebo and may have a minimal role in the management of patients with HE. 25 
Probiotics
Probiotics alter gut flora, resulting in decreased ammonia production and absorption. Patients taking probiotics were found to have fewer breakthrough episodes in comparison with placebo; however, this was not true when compared with lactulose. Studies indicate that probiotics may have a secondary prophylactic role, specifically reducing the severity and number of HE episodes. 26, 27 Pharmacological Interventions
Nonabsorbable Disaccharides
The American Association for the Study of Liver Disease and European Association for the Study of the Liver guidelines recommend treatment of an OHE episode with a 4-pronged approach: initiation of care for patients with altered consciousness, alternative causes of altered mental status reviewed and treated, identification of precipitating factors, and commencement of empirical HE treatment. The nonabsorbable disaccharide lactulose is often used as the first-line treatment for OHE, at a dose of 25 mL (16.7 g) every 12 hours until at least 2 soft or loose bowel movements result, with maintenance dosing titrated to 2 to 3 bowel movements per day. 8 Lactulose ameliorates OHE by various proposed mechanisms. When metabolized by gut bacteria, it leads to increased bacterial mass and nitrogen incorporation by the bacteria, which in turn, increases fecal nitrogen. As a result of lactulose metabolism, gut bacteria produce organic acids, which reduce the breakdown of nitrogen-containing compounds to ammonia and other cerebral toxins. Moreover, the organic acid traps ammonium ions in the gut. Lactulose may even inhibit intestinal glutamine uptake, decreasing ammonia production. 28, 29 Another nonabsorbable disaccharide used in the treatment of OHE is lactitol, a derivative of lactose available in a powder dosage form. 8 It is not as sweet as lactulose and produces less flatulence. 30 Lactitol is currently not available in the United States.
Orlandi et al 31 Als-Nielsen et al 33 conducted a systematic review of 22 randomized trials that compared nonabsorbable disaccharides-lactulose or lactitol-with placebo, no treatment, or antibiotics in patients with acute HE, chronic HE, or MHE. Overall, when evaluating lactulose versus placebo or no intervention, the authors found favorable evidence for the use of lactulose or lactitol. Patients in the placebo or no intervention group were at higher risk of no improvement [relative risk (RR) = 0.62; 95% CI = 0.46-0.84]. There was no beneficial effect of lactulose or lactitol in comparison with placebo or no intervention on mortality or the number connection test. Adverse events reported in the trials were diarrhea, flatulence, abdominal pain, and nausea. When comparing lactulose or lactitol versus antibiotics, patients were at higher risk of no improvement (RR = 1.24; 95% CI = 1.02-1.50), and there was no significant difference between the 2 groups when evaluating mortality. Adverse events reported were related to gastrointestinal function, including nausea, abdominal pain, flatulence, and diarrhea; incidence was similar to the placebo analysis. 33 Huang et al 34 conducted a cost-effectiveness and budget impact analysis of 6 strategies utilized for managing HE, comparing no therapy, lactulose monotherapy, lactitol monotherapy, neomycin monotherapy, rifaximin monotherapy, and lactulose monotherapy with rifaximin salvage. Of note, the authors found that rifaximin monotherapy is not cost-effective. In contrast, lactulose monotherapy with rifaximin salvage was less expensive and more effective than therapy with comparators. 34 Another small retrospective study of 39 patients compared mean total treatment cost per year, including costs associated with drug therapy, emergency department visits, and hospitalizations. The study showed that lactulose therapy had a higher total treatment cost per year in comparison to rifaximin, even though mean lactulose drug cost is less than that of rifaximin. 35 Recently, the HELP randomized clinical trial was published comparing lactulose with polyethylene glycol 3350-electrolyte solution (PEG) for the treatment of HE to determine if patients with HE would benefit from rapid catharsis of the gut. A total of 50 patients were enrolled, with the primary outcome of improvement of 1 or more in the HE grade at 24 hours using the HE Scoring Algorithm (HESA). The HESA ranges from 0, indicating no evidence in HE, to 4, indicating coma. The authors found a significant reduction in HESA score with a mean decrease of 0.7 in the lactulose group and 1.5 in the PEG group (P = 0.002). Adverse events were uncommon. 36 
Neomycin
Historically, neomycin was widely used for the treatment of HE. Neomycin acts by inhibiting the activity of glutaminase, consequently decreasing ammonia production from glutamine in the intestinal mucosa. 37 Its primary effect is likely a reduction of bacteria-associated ammonia. As previously reviewed above, Orlandi et al 31 found no difference in transition to lower-grade HE when comparing neomycin with lactulose. Moreover, neomycin's side effect profile includes ototoxicity, nephrotoxicity, and risk of enterocolitis. The guidelines recommend neomycin as an alternative choice for the treatment of OHE. 8 
Metronidazole
The use of metronidazole for the treatment of OHE has been suggested for short-term use. 8 The postulated mechanism behind the utility of metronidazole in HE revolves around the agent's activity against anaerobic gut flora. The anaerobic bacteria have urease activity, leading to hydrolysis of urea to ammonia and other toxins. Therefore, the killing of these anaerobic bacteria will decrease ammonia production. One trial compared neomycin 1 g with metronidazole 0.2 g administered orally 4 times a day for 1 week in a total of 18 patients, in a crossover design, so that patients served as their own controls and received both antibiotics. The patients were divided into 2 groups: those having mild or moderate and those having severe features of encephalopathy. The study found that in both groups, metronidazole did significantly improve mental status scores and asterixis, as did neomycin. Thus, the authors concluded that metronidazole may be as effective as neomycin. 38 The trial did not report adverse effects; however, long-term use of metronidazole is associated with more serious side effects of nephrotoxicity, ototoxicity, and neurotoxicity in comparison to other agents used to treat HE. 38 Thus, metronidazole is considered an alternative choice but is not recommended for long-term treatment of HE. 8 
Vancomycin
Vancomycin is a nonabsorbable antibiotic that has been studied for the treatment of HE. Although vancomycin is used clinically in the treatment of infections caused by Gram-positive bacteria, in its use for HE, Tarao et al 39 report that it also reduces the count of Gram-negative anaerobic rods in the stool, which are thought to actively produce urease leading to ammonia production. In Japan, 12 lactuloseresistant patients received oral vancomycin 1 g twice daily in a single-blind trial for 8 weeks followed by randomization to a crossover trial of vancomycin versus lactulose titrated to 2 to 4 bowel movements per day for a total of 16 weeks. In the single-blind portion of the study, all 12 patients observed improvement in HE grade after vancomycin therapy (P < 0.001),which was seen after 2 to 3 days of therapy. Moreover, patients who crossed over to lactulose therapy experienced worsening mental status after the switch. 39 This small, single-blinded study suggests that vancomycin may be an option in patients who are unresponsive to lactulose therapy. However, caution should be used because there is little evidence. The use of vancomycin in HE should be discouraged because other viable options are available.
Rifaximin and Rifaximin Combination Therapy
Rifaximin is a broad-spectrum, minimally absorbed oral antibiotic, with activity against Gram-negative and -positive aerobes and anaerobes in the gut that has been shown to be equivalent or superior to other agents in the treatment of HE. 8, 40 One study evaluated the efficacy and safety of rifaximin 550 mg twice a day in a phase 3, multicenter, randomized, double-blind, placebo-controlled trial over 6 months. Of note, adjunctive lactulose was permitted in both groups. The primary outcome of a breakthrough episode of HE occurred in 22.1% of patients in the rifaximin group in comparison to 45.9% in the placebo group. The authors found a significant reduction in the risk of an HE episode [hazard ratio (HR) = 0.42; 95% CI = 0.28-0.64; P < 0.001]. The use of lactulose in both groups was similar. 41 Kimer et al 40 conducted a systematic review with meta-analysis of 19 studies comparing rifaximin versus a control group consisting of placebo, nonabsorbable disaccharides, and antibiotics. The study demonstrated a beneficial effect of rifaximin on HE resolution in comparison to the controls (RR = 1.34; 95% CI = 1.11-1.62). Overall, the number needed to treat was 6. More specifically, rifaximin prevented OHE (RR = 1.36; 95% CI = 1.06-1.65), increased HE recovery (RR = 0.59; 95% CI = 0.46-0.76), and reduced mortality (RR = 0.68; 95% CI = 0.48-0.97). Of note, none of the trials included in the analysis found an increased antimicrobial resistance to rifaximin or Clostridium difficile infection. Adverse drug reactions were mainly gastrointestinal. 40 As previously stated, rifaximin monotherapy was found to be not cost-effective. 34 Sharma et al 42 conducted a study comparing the use of lactulose plus rifaximin versus lactulose alone in 120 patients to determine the efficacy and safety of combination therapy over monotherapy for the treatment of OHE. The authors found a significant increase in HE reversal within 10 days, in favor of combination therapy: 76% versus 44% (P = 0.004). Moreover, combination therapy was associated with a significant decrease in length of stay in the hospital (P = 0.001) as well as decrease in mortality (P < 0.05). Furthermore, the authors found an association with high baseline leukocyte count and failure of lactulose monotherapy. No serious side effects were reported. Gastrointestinal symptoms, including diarrhea and abdominal pain, occurred in both groups. 42 This study suggests that combination therapy may be appropriate in the treatment of OHE. As previously stated, combination therapy was found to be efficacious and most cost-effective when rifaximin was used as salvage therapy. 34 Currently, the guidelines recommend the use of rifaximin as add-on therapy to lactulose for the prevention of OHE recurrence. 8 As for maintenance therapy, continuation of agents used in the acute management of HE, either lactulose alone or in combination with rifaximin, may be utilized for the prevention of recurrent episodes. 8
Future Trends and Developments
First-line pharmacological interventions for managing HE manifestations exert their effects by either reducing ammonia production by bacteria in the colon or by lessening ammonia absorption by altering the colonic pH. 43 Currently, there are alternative therapies for patients who are nonresponsive or unable to tolerate the standard treatments. 44 As previously described, it has been hypothesized that in liver failure, peripheral GABA may be able to more easily penetrate the blood-brain barrier and inhibit neuronal function; the brain may be more susceptible to GABA-ergic neuronal inhibition; or an increased number of drug-binding sites may increase sensitivity to endogenous benzodiazepine receptor ligands. 10 Similarly, because Parkinson-like extrapyramidal symptoms have been observed in patients with HE, it has been postulated that dopamine agonists could have a role in modulating symptoms of HE. [45] [46] [47] Direct neurological therapies such as bromocriptine and flumazenil may affect these physiological features and may alleviate symptoms of HE in certain individuals. Additionally, ammonia-eliminating agents such as l-ornithine l-aspartate (LOLA) and sodium benzoate are potential drug options that may be important adjunctive therapies in patients with severe or persistent overt symptoms of HE. 44, 48 
Dopamine Agonists
Bromocriptine, a dopamine receptor agonist approved for Parkinson's disease, may benefit reduced dopaminergic neurotransmission, which is a postulated mechanism for development of HE. [44] [45] [46] [47] In one study of 6 patients who had all failed standard therapy, those on adjunctive bromocriptine showed improvement in mental state, in terms of increased concentration and memory quality, as well as significant improvements in mean EEG frequency (P < 0.05). 45 Patients who crossed over to placebo following an 8-to 12-week period on bromocriptine showed quicker clinical deterioration than patients who crossed over to placebo after 16 to 20 weeks of bromocriptine therapy. 45 No beneficial effects were observed in patients who were already stabilized using standard treatment; in this cohort, bromocriptine did not display significantly superior outcomes to placebo treatment and was always inferior to standard treatment. 46 A recent meta-analysis of 5 trials that included both levodopa and bromocriptine concluded that there is no evidence to recommend or refute the use of dopamine agents in the treatment of HE. 47 Recommendations for the use of bromocriptine cannot be made for chronic HE patients who are adequately controlled using standard therapy; rather, this agent can be considered a safe and welltolerated option for refractory patients in the event that first-line therapies prove ineffective. 45, 46 Flumazenil Flumazenil has demonstrated a role in selected and severe HE cases where a history of benzodiazepine intake may be a contributing factor. [49] [50] [51] [52] Compared with placebo, use of the short-acting benzodiazepine receptor antagonist has shown significant improvement in neurological scores and EEG tracings in grade III and grade IVa patients who were nonresponsive to standard therapy. [49] [50] [51] [52] Similar results were seen in a meta-analysis of 6 double-blind, randomized controlled trials comparing flumazenil and placebo in cirrhotic patients with HE. 50 Additionally, a specific subset of HE patients who experienced bleeding saw beneficial effects; it was also noted that a lack of response was typically associated with a high early mortality rate. 51 Although flumazenil yielded significant short-term improvements, there was no significant effect on long-term benefits or survival improvement. 52 Until improvement in recovery is demonstrated, flumazenil should not be administered for routine clinical use, though it may be considered for select patients with chronic liver disease and HE. 52 Of note, no seizures were observed in these studies and analyses; however, most studies evaluating the use of flumazenil in the treatment of HE have excluded patients with recent benzodiazepine use. 50 
Ornithine Aspartate
LOLA is a stable salt made up of 2 amino acids that can increase ammonia metabolism through the urea cycle and glutamine synthesis pathways. 48 Oral administration of LOLA in advanced grade I and II patients resulted in positive effects but did not appear to affect patients of subclinical status. 53 Other studies over the past 2 decades have additionally shown that the ammonia-reducing therapy can improve mental status, portosystemic encephalopathy index (PSEI), performance in the number connection test A, asterixis, and EEG activity, without serious adverse events. [53] [54] [55] [56] [57] Despite preliminary efficacy, there are limitations in its availability in the United States. 43 Overall, LOLA has been evaluated to be a safe, effective, and welltolerated short-term alternative therapy in cirrhotic patients with stable, chronic OHE. 56 
Sodium Benzoate
Cirrhotic patients with acute HE may find sodium benzoate to be a safe and effective alternative to lactulose. 58 Serum ammonia levels can be decreased with sodium benzoate because of its mechanism of binding to glycine and glutamine to form hippurate, which is then excreted into the urine, ultimately providing an alternative form of nitrogenous waste elimination. 58 The inexpensive adjunctive agent has shown promise as a third-or fourth-line option in patients with good kidney function who are unable to tolerate standard therapy or have persistent or episodic HE despite the standard regimen. 48, 59 Significant improvement (P < 0.001) was measured in cognition, memory, and PSEI in patients with cirrhosis or portal-systemic shunts. 58 Potential limitations of sodium benzoate included association with large sodium content and gastrointestinal symptoms that were not ameliorated by dose reduction. 58, 59 One study yielded contrasting results-namely, increased basal and postglutamine ammonia levels were seen in cirrhotic patients without OHE. 43 Taking these factors into consideration, sodium benzoate may be an appropriate alternative to lactulose in acute HE, but it may not be a suggested therapeutic option for all patients. 59 Thus far, these alternative therapies have demonstrated varying degrees of efficacy and in particular cohorts or subgroups of patients with HE. More robust studies in larger cohorts of patients with HE are needed; until then, these agents should be considered as adjuncts or alternatives to standard treatments when those therapies are intolerable or have failed.
Conclusion
Management of HE represents a clinical challenge to practitioners working in all patient care settings. The pathophysiology of this manifestation of chronic liver disease is still not completely understood; traditional therapies aimed at reducing serum ammonia levels represent the mainstay of therapeutic management. Optimal strategies for administering ammonia-lowering agents continue to change, as does the literature and role for alternative treatment options, including dietary modification and use of other therapeutic agents that work to modulate neurotransmitter function. The practicing clinician who encounters patients with chronic liver disease must keep abreast of updates to guidelines and evidence as recommendations for the management of this condition continue to evolve.
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